A COMPARATIVE STUDY OF EFFICACY AND SAFETY OF AZILSARTAN 40MG AND TELMISARTAN 40MG IN STAGE I HYPERTENSIVE PATIENTS ATTENDING CARDIAC OPD AT TERTIARY CARE HOSPITAL

M. SNEHA MANJU; SWATHI MIRYALA; PERAVALI ARPANA RACHEL; MAHESH KUMAR K.; GOURELLY LATHA

doi:10.22159/ijpps.2023v15i2.46637

Authors

M. SNEHA MANJU Department of Pharmacology, Osmania Medical College Hyderabad, Telangana 500095, India
SWATHI MIRYALA Department of Pharmacology, Osmania Medical College Hyderabad, Telangana 500095, India https://orcid.org/0000-0002-6788-9698
PERAVALI ARPANA RACHEL Department of Pharmacology, Osmania Medical College Hyderabad, Telangana 500095, India https://orcid.org/0000-0002-1486-8463
MAHESH KUMAR K. Department of Pharmacology, Osmania Medical College Hyderabad, Telangana 500095, India
GOURELLY LATHA Department of Pharmacology, Osmania Medical College Hyderabad, Telangana 500095, India

DOI:

https://doi.org/10.22159/ijpps.2023v15i2.46637

Keywords:

Hypertension, Telmisartan, Azilsartan

Abstract

Objective: To study the efficacy and safety profile of Telmisartan 40 mg and Azilsartan 40 mg in stage I systemic Hypertension among patients attending cardiac OPD in a tertiary care center.

Methods: An open-labeled comparative study was conducted in the Department of Cardiology, Osmania General Hospital, Hyderabad, for 24 mo. All patients with stage I systemic hypertension of either sex, aged 18-65 y, with blood pressures of >140/90 mmHg and/or diabetes mellitus attending the cardiac outpatient department at Osmania General Hospital. After initial screening, diagnosed cases of essential hypertension were randomly allocated to either group 1 (Tablet Azilsartan 40 mg or group 2 (Tablet Telmisartan 40 mg). The patients were advised to report for follow-up for review on the 4^th, 8^th, 12^th, and 24^th week.

Results: The mean decrease in the systolic blood pressure in both groups was statistically significant with a P value of<0.05 at the 8th week, 12th week, and the end of the 24th week. The mean decrease in diastolic blood pressure in both groups was statistically significant with a P value of 0.01 at the end of the 24^th week. The difference between the SBP and DBP at various intervals is statistically significant with an Anova P value of<0.0000001.

Conclusion: Both drugs controlled blood pressure at similar proportions. However, the mean of SBP and DBP for the Azilsartan group was lower than the Telmisartan Group. Both drugs were tolerated well, and no significant adverse effects were noted during the study.

Downloads

Download data is not yet available.

References

Esunge PM. From blood pressure to hypertension: the history of research. J R Soc Med. 1991 Oct;84(10):621. doi: 10.1177/014107689108401019, PMID 1744849, PMCID PMC1295564.

Kotchen TA. Historical trends and milestones in hypertension research: a model of the process of translational research. Hypertension. 2011 Oct;58(4):522-38. doi: 10.1161/hypertensionaha.111.177766. PMID 21859967.

Centers for Disease Control and Prevention. High blood pressure facts Atlanta, GA. Centers for Disease Control and Prevention; 2011. Available from: http://www.cdc.gov/bloodpressure/facts.htm. [Last accessed on 24 Jul 2011]

Katherine T. Mills, Andrei Stefanescu, Jiang He. The global prevalence of hypertension. Nat Rev Nephrol. 2020 Apr;16(4):223-37. doi: 10.1038/s41581-019-0244-2.

Anchala R, Kannuri NK, Pant H, Khan H, Franco OH, Di Angelantonio E. Hypertension in India: a systematic review and meta-analysis of prevalence, awareness, and control of hypertension. J Hypertens. 2014 Jun;32(6):1170-7. doi: 10.1097/HJH.0000000000000146, PMID 24621804, PMCID PMC4011565.

National High Blood Pressure Education Program. The seventh report of the Joint National Committee on Prevention, detection, evaluation, and treatment of high blood pressure. Bethesda: National Heart Lung and Blood Institute. US; 2004 Aug. Available from: https://www.ncbi.nlm.nih.gov/books/NBK9630.

Bir Singh P, Singh S, Gill GK. Role of combination drug therapy for the management of hypertension with increasing age. Asian J Pharm Clin Res. 2021;14(10, Oct):53-8. doi: 10.22159/ajpcr.2021.v14i10.42431.

Sharma S, Kumar Singh S, Baranwal PK, Singh DK, Kale V. A cross-sectional study to estimate the prevalence of hypertension in urban field practice area of medical college in the metropolitan city of India. Asian J Pharm Clin Res. 2022;15(9):98-101. doi: 10.22159/ajpcr.2022.v15i9.45926.

Angeloni E. Azilsartan medoxomil in the management of hypertension: an evidence-based review of its place in therapy. Core Evid. 2016 Apr 5;11:1-10. doi: 10.2147/CE.S81776. PMID 27103882, PMCID PMC4829189.

Karen W, Finkel R, Panavelil TA. Lippincott illustrated reviews: pharmacology. 6th ed. Vol. 225. Philadelphia: Wolters Kluwer; 2015.

Pagani M. Ipertensione arteriosa, stress e betablocco [Arterial hypertension, stress, and beta-blockers]. Cardiologia. 1993 Dec;38(12);Suppl 1:435-42. PMID 7912651.

Barutçuoglu B, Parildar Z, Mutaf MI, Ozmen D, Alİoglu E, Habİf S. Effect of telmisartan on vascular endothelium in hypertensive and type 2 diabetic hypertensive patients. Turk J Med Sci. 2010;40(2):11. doi: 10.3906/sag-0807-11.

Boehringer Ingelheim Pharma. Drug prescribing information: Micardis; 1998.